A new procedure was developed and applied to study immunoglobulin free light chains (FLC) in saliva of healthy subjects and patients with multiple sclerosis (MS). The procedure was based on a Western blot analysis for detection and semiquantitative evaluation of monomeric and dimeric FLCs. The FLC indices accounting for the total FLC levels and for the monomer/ dimer ratios of j and k FLC were calculated, and the cut-off values of the FLC indices were determined to distinguish healthy state from MS disease. The obtained FLC index values were statistically different in the saliva of three groups: active MS patients, MS patients in remission and healthy subjects groups. Our FLC monomer-dimer analysis allowed differentiation between healthy state and active MS with specificity of 100% and a sensitivity of 88Á5%. The developed technique may serve as a new noninvasive complementary tool to evaluate the disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%.
Introduction
Multiple sclerosis (MS) is a putatively autoimmune inflammatory disease of the central nervous system (CNS) affecting mainly relatively young adults. The diagnosis of MS is based on clinical and paraclinical tests including magnetic resonance imaging, as well as analysis of cerebrospinal fluid (CSF), where demonstration of oligoclonal immunoglobulins (Ig) indicates intrathecal Ig production typical of MS. Although the oligoclonality test is used commonly in MS management, the oligoclonal Ig might be detected in other inflammatory and infectious CNS diseases, thus reducing the utility of this method for differential diagnosis.
During the last decade, the intrathecal production of not only intact Ig, but also of Ig free light chains (FLC), gained considerable interest in the diagnosis of MS. An increasing body of evidence suggests strongly that intrathecal production of FLC is markedly elevated in MS, and that quantification of FLC in CSF may contribute to the diagnosis [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] and to the understanding of the pathogenesis of MS [11, 12] .
Recently, we have developed a new Western blot-based technique to analyse FLC monomers and dimers in CSF of MS patients [3] [4] [5] [6] [7] . Both specificity and sensitivity of our diagnostic method of MS are higher than those of the conventionally used oligoclonality test [3, 7] . In addition, we observed three abnormal FLC patterns in MS patients, characterized by increased levels of either j FLC (monomers and dimers) or k FLC dimers, or both (i.e. j monomers and dimers plus k dimers). The clinical significance of such differences in FLC patterns is currently under investigation.
Although useful in diagnosis and management, the repeated testing of CSF for the follow-up of MS patients is impractical for being invasive. We hypothesized that FLC analysis of the patients' saliva might be more useful for this purpose. This assumption is based on earlier reports on changes in mucosal immunity in MS, including: increased numbers of immunoreactive cells in saliva and tears [13, 14] , impairment of mucosal barrier of the gut ('leaky gut') [15] and presence of oligoclonal Ig bands and increased amounts of monomeric IgA and IgG in tears [16] [17] [18] .
In the current study, we examine the efficacy of the saliva FLC testing for the diagnosis and disease activity evaluation in MS. We report a new technique for analysis of the monomeric and dimeric FLC in saliva and compare the FLC monomerdimer patterns in MS patients with those of healthy subjects.
Materials and methods

Study overview
Here we describe the development of a non-invasive practical test, based on a semiquantitative Western blot analysis of FLCs in saliva. The developed technique was used to evaluate total levels of saliva FLCs and the ratios of FLC monomer and dimers. We found this technique to be useful in distinguishing between patients with active MS and healthy subjects, and between MS patients with active disease and those in remission. The study was approved by the institutional review board.
Patients and samples
Patients with a definite diagnosis of MS (n 5 85, aged 20-65 years, mean age 45Á3 6 13Á2) were studied. MS diagnosis was based on revised McDonald criteria [19] . Seventy-three of 85 MS patients showed the relapsing-remitting form of the disease (RR-MS), and the remaining 12 patients had a secondary progressive course (SP-MS). MS patients were under at least one of the following treatments: interferon beta-1a (IFN-b1a), interferon beta-1b, dimethyl fumarate, fingolimod, glatiramer acetate and naltrexone (Table 1) .
Saliva samples of MS patients were collected during their regular visits at the MS Clinical Research and Treatment Service of a large tertiary Medical Center. On the day of saliva sampling patients underwent clinical evaluation to determine their expanded disability status scale (EDSS) scores. Also, the EDSS scores were determined 3 months prior to and after sampling, as part of patients' evaluation during their regular follow-up visits. Based on patients' files, three subgroups of MS patients were defined: the RR-MS patients in remission (n 5 58), the RR-MS patients with relapse of the disease (n 5 15) and SP-MS patients (n 5 12) (Tables 2-4) . Patients with relapse showed worsening of old symptoms or the appearance of new MS symptoms that lasted more than 24 h. Some patients with relapse received a course of treatment with steroids, as indicated in Table 2 .
The control group included 28 healthy individuals (17 females). The age of control group individuals ranged from 20 to 60 years (mean age 38Á7 6 11Á2) and was similar to that of MS patients. Healthy individuals showed no evidence for neurological, inflammatory or any other chronic disease; monoclonal gammopathy was also excluded. Saliva samples were collected from 28 healthy individuals; serum samples were collected from four healthy individuals.
Sample preparation
Saliva samples (approximately 0Á5 ml) were collected during the morning hours (from 8 to 12 a.m.) by spitting, and stored in 1Á5 ml Eppendorf tubes at 2308C until use. Before testing, the saliva samples were centrifuged at 16 000 g for 20 min in the Eppendorf centrifuge (Eppendorf 5415C; Marshal Scientific, Hampton, NH, USA). The supernatant aliquots were dried in a SpeedVac apparatus (SpeedVac Sc100; Savant, Farmingdale, NY, USA) and redissolved in electrophoresis sample buffer containing 0Á2 mol/l sucrose, 6% sodium dodecyl sulphate (SDS), 125 mmol/l hydroxylmethylaminomethane (Tris), 4 mmol/l Na 2 ethylenediamine tetraacetic disodium salt (EDTA). Equal volumes of the obtained samples were applied for their analysis by Western blot technique.
Western blotting
Western blotting was performed as described [3, 7] . Briefly, samples were run by SDS-electrophoresis, using highresolution 10-20% Nu-Sep Tris-Tricine gels (Gradipore, Frenchs Forest, New South Wales, Australia) under non- 
Quantification of intensity of immunoreactive bands
Software [3, 7] was used to quantify the intensity of FLC immunoreactive bands (FLC monomers and covalently bound dimers). The obtained immunoreactivity values in the tested samples were normalized against that of a control sample, by dividing the intensity (I) of the tested samples by that of the control: I tested sample /I control sample . The control sample comprised a mixture of saliva samples obtained from 23 of 28 healthy individuals participating in this study. A control sample was included in each electrophoretic run alongside the tested samples.
Total protein determination in saliva samples
Saliva supernatant aliquots were diluted (1 : 10) and analysed using the pyrogallol red-molybdate complex method [20] on Beckman Coulter analyser (Beckman Coulter, Inc., Brea, CA, USA).
Statistical analysis
Confidence intervals were calculated for the indices accounting for total FLC level, j monomer/dimer (M/D) ratio and k M/D ratio in active MS patients, MS patients in remission and healthy subject groups. The non-parametric Mann-Whitney U-test was also applied to compare the FLC indices in these three groups.
Results
Optimization of experimental conditions using normal saliva
Saliva samples of three healthy individuals were centrifuged, and the obtained supernatants were collected for further examination. To determine optimal sample dilution, saliva supernatant aliquots ranging between 0Á9 and 30 ll were dried and then redissolved in equal amounts of electrophoresis sample buffer. Equal amounts of the prepared samples were subjected to Western blot analysis. Figure 1a demonstrates the relationship between chemiluminescence signal and saliva content in a sample obtained from one of the healthy individuals. Similar results were obtained by analysing saliva samples of two other healthy individuals. Figure 1b demonstrates the linearity range suitable for the FLC monomer and dimer measurements. We observed linearity of the chemiluminescence signal in a range from 0Á015 to 0Á06 that corresponded to the range of 5-15 ll of saliva supernatant used for sample preparation. Figure 2 demonstrates Western blot analysis of the monomeric (25 kDa) and dimeric (50 kDa) j and k FLC in saliva of eight healthy subjects. Although the FLC monomer and dimer levels varied among different individuals, most of them (22 of 28) showed predominance of dimeric compared to monomeric FLC (j and k). In fact, the FLC monomers dominated in only six of the 28 healthy saliva samples. FLC monomer-dimer patterns in saliva and serum samples of four healthy individuals were examined (Fig. 3) . FLC patterns in serum differed considerably from those in saliva by showing either moderate or mild predominance of monomeric versus dimeric FLC. The observed patterns of FLC monomers and dimers in serum were in concordance with those obtained in our previous studies, where serum FLC patterns were examined in a larger number of healthy individuals (n 5 30) [21, 22] .
FLC analysis in healthy individuals
FLC indices for the total FLC level and for the M/D ratios of j and k FLC were estimated in saliva samples of 28 healthy individuals. The total FLC level indices varied from 1Á3 to 14Á1, the j M/D ratio indices varied from 0Á3 to 2Á3 and k M/D ratio indices varied from 0Á2 to 2Á2 (Table 5) .
To check whether food intake may affect the saliva FLC patterns of the same individual, we analysed saliva samples from five healthy subjects collected after overnight fasting and 1 h after the morning meal. Despite slight changes in FLC patterns before and after the meal (Fig. 4) , the obtained values were within the normal ranges, as shown in Table 5 .
FLC patterns in MS
FLC monomer-dimer patterns in the saliva of active MS patients (n 5 27, including 15 RR-MS with relapse and 12 SP-MS patients), MS patients in remission (n 5 58) and healthy individuals (n 5 28) were examined and compared. A large proportion of patients in remission (47 of 58) demonstrated FLC patterns comparable to those observed in healthy individuals (Fig. 5, tracks 2--5 ). In contrast to MS patients in remission, most active MS patients (24 of 27) tended to show either (a) an increase in the level of FLC monomers (j or k, or both) and/or (b) an increase in the total level of FLC (j monomers plus dimers and k monomers plus dimers). Figure 6 demonstrates FLC analysis in saliva of five active MS patients versus healthy individuals and versus patients in remission. As, in many cases, the FLC bands in saliva of active MS patients showed high chemiluminescence signals outside the linearity range, the samples were diluted further to allow valid quantification. An illustration of this approach is presented in Fig 7, which shows optimal sample dilutions suiting the linearity range.
The calculated FLC indices accounting for total FLC level and M/D ratios in saliva of active MS patients and patients in remission are presented in Tables (2-4) .
FLC indices distinguishing a healthy state from MS
Mean values of saliva FLC indices of healthy individuals (Table 5) (Fig.  8) . In contrast, in 23 of 27 patients with active MS at least one of these three FLC indices was above the cut-off value. Only three active MS patients (patients 16, 25 and 27) had normal FLC index values (below the cut-off values), and FLC indices in one patient (patient 5) were borderline (Table 3 and Fig. 8 ). Of note, for the appropriate interpretation of the data obtained, both j M/D and k M/D indices should be considered. For example, patient 22 showed abnormalities in the j M/D ratio index while the k M/D ratio index was normal, whereas for patients 8 and 26 determination of k M/D ratio indices was necessary to detect abnormalities in the FLC patterns (Fig. 8) .
Finally, the calculated saliva FLC indices of MS patients in remission (n 5 58) were normal (below cut-off values) in 43 patients, abnormally high in 11 patients and borderline in four patients (Table 4 , Fig. 9 ).
FLC index values are statistically different in active MS, MS in remission and healthy state groups
The 95% confidence intervals of the FLC indices of patients with active MS, MS in remission and healthy subject groups were distinct (non-overlapping) in all three groups with respect to total FLC level and k M/D ratio indices. There was, however, some overlap between MS patients in remission and those with active disease regarding the j M/ D ratio (Table 6 ). Nevertheless, the Mann-Whitney U-test showed that patients with active MS, MS patients in remission, as well as healthy subjects, differed significantly in all 
*The FLC indices in the individual samples (n 5 28) were computed using software [3, 7] to quantify the intensity of FLC immunoreactive bands. The obtained immunoreactivity value in the tested sample was divided by that of the control reference sample used throughout this study. (Table 7) . Finally, our technique differentiates between healthy state and active MS with a specificity of 100% and sensitivity of 88Á5%, and between remission and active MS with a specificity 80% and a sensitivity of 89% (borderline values were excluded from the calculations).
Discussion
In this study we have developed a new procedure based on a semiquantitative Western blot analysis to study FLC in saliva. The saliva samples of healthy subjects and those of MS patients were tested, and indices accounting for FLC monomer/dimer ratio and total FLC levels were calculated. The developed technique made it possible to discriminate between healthy state and active MS (specificity 100%, sensitivity 88Á5%) and between active MS and remission (sensitivity 89%, specificity 80%). The developed procedure is non-invasive, requires no expensive equipment and might be applied in clinical laboratories, as a new ancillary tool, to characterize the status of MS patients and their response to treatment.
To standardize the conditions of our technique, the saliva samples were collected and handled as equally as possible for all patients and control subjects. All saliva samples were centrifuged at the same speed to remove the cells and debris from the supernatant. As the salivary Ig levels may be affected by the rate of secretion and relation to meals [23] , we checked the influence of fasting status on the FLC patterns. Although some minor changes in the FLC levels were observed, they were insignificant and did not affect the diagnostic capability of our technique.
Another important standardization issue was related to total FLC level index calculation. In our study all measurements were carried out using equal volumes of tested samples, i.e. without adjustment to total protein concentration. The rationale for such an approach was based on studies which showed that relating the immunoglobulin level to total protein might be misleading due to large individual variations of secretory response of salivary proteins Fig. 6 . Western blot analysis of free light chain (FLC) monomers (25 kDa) and dimers (50 kDa) in saliva of five active multiple sclerosis (MS) patients (a2, b2, c2, d2, e2) versus healthy individuals (a1, b1) and versus patients in remission (c1, d2, e1) . Active MS patients demonstrate abnormally increased intensity of the immunoreactive FLC bands and increased proportion of FLC monomers compared to healthy individuals and MS patients in remission. Fig. 7 . Relationship between the chemiluminescence signal of free light chain (FLC) monomer (25 kDa) and dimer (50 kDa) bands (axis y) and amount of saliva in sample (axis x) of patient with active multiple sclerosis (MS). Saliva supernatant aliquots of 0Á156, 0Á132, 0Á625, 1Á25, 2Á5 and 5Á0 ll were dried and redissolved in 45 ll electrophoresis sample buffer. Equal amounts of the prepared samples were applied for Western blot analysis (10 ll/well). The displayed electrophoregram demonstrates the increasing intensity of FLC bands of these samples (tracks 1-6, respectively). In this case, 1Á25 ll of supernatant (used for sample preparation) was optimal for the intensity measurements within the linearity range. [23] [24] [25] . In addition, we have measured total protein concentration in 55 saliva samples (of 19 active MS patients, 22 patients in remission and 14 healthy individuals) by using the pyrogallol red-molybdate complex method [20] (data not shown). We found no significant correlation between total protein levels and total FLC level indices (two-tailed P 5 0Á112; R 2 5 0Á047 by Pearson's correlation test). Taken together, these findings refuted the possibility that increased values of total FLC index might be due to total protein increase.
Comparison of the FLC patterns of normal saliva and normal serum revealed striking differences, showing a predominance of dimers in the saliva samples and monomers in the sera. We hypothesize that this difference stems from the structural differences of the Ig contained in the saliva and in the serum. While the saliva Ig are made mainly of the locally synthesized IgA1 and IgA2 isotypes, the serum Ig are mainly IgG. Further, in contrast to other Ig classes, the IgA2 heavy chains are bound to dimeric, not monomeric, light chains [26] , therefore production of a larger amount of dimeric light chains may be needed for the biosynthesis of intact IgA2 molecules. Thus, most probably, the differences in FLC monomer-dimer patterns observed in normal saliva versus serum are related to a higher proportion of the IgA2 synthesizing B cells in oral mucosa which produce larger amounts of dimeric light chains, compared to the peripheral B cells synthesizing other Ig molecules.
Our study found that most patients with active MS undergo changes in their saliva FLC patterns, which show a higher proportion of monomeric FLC, as follows from their j M/D or k M/D indices (Tables 2 and 3 ). The reason for this change still needs to be determined, but it could be speculated that it is due to a local switch in the biosynthesis from IgA2 to IgA1 or IgG, leading to increased production of monomeric FLC. Alternatively, it may be due to penetration of peripheral B lymphocytes to oral mucosa and production of larger amounts of monomeric FLC.
The non-overlapping confidence intervals of saliva FLC indices (Table 6 ) suggest that FLC patterns of MS patients in remission place them between normal individuals and MS patients with active disease. This finding lends further support to the view that even during clinical remission there is a subtle immunological activity, which may need special attention and perhaps certain measures for suppression. Fifteen of 58 patients in remission continued to have higher than normal FLC indices, thus suggesting ongoing immunological activity despite perceived clinical remission. It is already known that MS flare may be preceded by T cell and B cell activity months before the clinical flare [27, 28] . Whether our finding has treatment implications still needs to be investigated.
It is also worth mentioning that four of 27 active MS patients had FLC indices lower than the cut-off values, and thereby failed to fulfil the saliva FLC criteria of active disease. Except for patient 5, who had borderline FLC indices, the other three patients were of the SP-MS type and had high EDSS scores ranging from 4Á5 to 7Á5 (Table  3) . As the immunopathological mechanisms underlying the SP and RR-MS forms are different [29, 30] , analysis of a larger number of MS cases (RR-MS with relapse and SP-MS) is needed to compare the diagnostic efficacies of our methodological approach in these two distinct subsets of active MS.
In conclusion, we have developed a new technique to analyse monomeric and dimeric FLCs in the saliva of MS patients. Application of this technique revealed deviation from the normal FLC monomer-dimer profile in the saliva of patients with active MS, while these pathological changes were absent in a large number of MS patients in remission. We think that our technique offers an easy, simple and non-invasive way to follow the disease course. Further studies, including longitudinal monitoring of the saliva FLC profiles in the individual MS patients, might be helpful in therapeutic decisions and in generation of new insights on the immunopathology of MS. M/D 5 monomer/dimer. Table 7 . Comparison of free light chain (FLC) indices between multiple sclerosis (MS) patients and healthy subjects using the Mann-Whitney U-test
Total FLC index j M/D ratio index k M/D ratio index MS patients in remission versus healthy individuals P 5 0Á0008 P 5 0Á007 P 5 0Á003 MS patients in remission versus active MS patients P < 0Á0001 P 5 0Á0002 P < 0Á0001 Active MS patients versus healthy individuals P < 0Á0001 P 5 0Á0002 P < 0Á0001
